Negative regulation of Toll-like receptor signalling;Negatywna regulacja sygnalizacji receptorów Toll-podobnych

Postepy Higieny i Medycyny Doswiadczalnej

Volumn 67, Issue , 2013, Pages 339-351

  Antosz, Halina ^a   Choroszyńska, Dorota ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

A20; CYLD; IRAK M; NOD2; RP105; SARM; SHP; SIGIRR; SMYD88; SOCS; ST2L; TOLLIP; TRAIL; arrestin

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; IRF3 PROTEIN, HUMAN; PATTERN RECOGNITION RECEPTOR; SIGNAL PEPTIDE; SUPPRESSOR OF CYTOKINE SIGNALING; TOLL LIKE RECEPTOR; TOLLIP PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

ANTIGEN PRESENTATION; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; REVIEW; SIGNAL TRANSDUCTION;

ANTIGEN PRESENTATION; CYTOKINES; HUMANS; IMMUNITY, INNATE; INTERFERON REGULATORY FACTOR-3; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-KAPPA B; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS;

EID: 84883187280     PISSN: 00325449     EISSN: 17322693     Source Type: Journal    
DOI: 10.5604/17322693.1046538     Document Type: Article

References (125)

1. Albiger B., Dahlberg S., Henriques-Normark B., Normark S.: Role of the innate immune system in host defence against bacterial infections: focus on the Toll-like receptors. J. Intern. Med., 2007;261:511-528
2. Ashkenazi A., Dixit V. M.: Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol., 1999;11:255-260
3. Balaci L., Spada M. C., Olla N., Sole G., Loddo L., Anedda F., Naitza S., Zuncheddu M. A., Maschio A., Altea D., Uda M., Pilia S., Sanna S., Masala M., Crisponi L., Fattori M., Devoto M., Doratiotto S., Rassu S., Mereu S., Giua E., Cadeddu N. G., Atzeni R., Pelosi U., Corrias A., Perra R., Torrazza P. L., Pirina P., Ginesu F., Marcias S., Schintu M. G., Del Giacco G. S., Manconi P. E., Malerba G., Bisognin A., Trabetti E., Boner A., Pescollderungg L., Pignatti P. F., Schlessinger D., Cao A., Pilia G.: IRAK-M is involved in the pathogenesis of early-onset persistent asthma. Am. J. Hum. Genet., 2007;80:1103-1114
4. Balakirev M. Y., Tcherniuk S. O., Jaquinod M., Chroboczek J.: Otubains: a new family of cysteine proteases in the ubiquitin pathway. EMBO Rep., 2003;4:517-522
5. Beutler B.: Inferences, questions and possibilities in Toll-like receptor signalling. Nature, 2004;430:257-263
6. Boone D. L., Turer E. E., Lee E. G., Ahmad R. C., Wheeler M. T., Tsui C., Hurley P., Chien M., Chai S., Hitotsumatsu O., McNally E., Pickart C., Ma A.: The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol., 2004;5:1052-1060
7. Borm M. E., van Bodegraven A. A., Mulder C. J., Kraal G., Bouma G.: The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype. Genes Immun., 2008;9:274-278
8. Brint E. K., Xu D., Liu H., Dunne A., McKenzie A. N., O'Neill L. A., Liew F. Y.: ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol., 2004;5:373-379
9. Brissoni B., Agostini L., Kropf M., Martinon F., Swoboda V., Lippens S., Everett H., Aebi N., Janssens S., Meylan E., Felberbaum-Corti M., Hirling H., Gruenberg J., Tschopp J., Burns K.: Intracellular trafficking of interleukin-1 receptor I requires Tollip. Curr. Biol., 2006;16:2265-2270
10. Bulut Y., Faure E., Thomas L., Equils O., Arditi M.: Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J. Immunol., 2001;167:987-994
11. Burns K., Clatworthy J., Martin L., Martinon F., Plumpton C., Maschera B., Lewis A., Ray K., Tschopp J., Volpe F.: Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor. Nat. Cell Biol., 2000;2:346-351
12. Burns K., Janssens S., Brissoni B., Olivos N., Beyaert R., Tschopp J.: Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med., 2003;197:263-268
13. Carty M., Goodbody R., Schröder M., Stack J., Moynagh P. N., Bowie A. G.: The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat. Immunol., 2006;7:1074-1081
14. Chamaillard M., Hashimoto M., Horie Y., Masumoto J., Qiu S., Saab L., Ogura Y., Kawasaki A., Fukase K., Kusumoto S., Valvano M. A., Foster S. J., Mak T. W., Nuñez G., Inohara N.: An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol., 2003;4:702-707
15. Couillault C., Pujol N., Reboul J., Sabatier L., Guichou J. F., Kohara Y., Ewbank J. J.: TLR-independent control of innate immunity in Caenorhabditis elegans by the TIR domain adaptor protein TIR-1, an ortholog of human SARM. Nat. Immunol., 2004;5:488-494
16. del Fresno C., Otero K., Gómez-García L., González-León M. C., Soler-Ranger L., Fuentes-Prior P., Escoll P., Baos R., Caveda L., García F., Arnalich F., López-Collazo E.: Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J. Immunol., 2005;174:3032-3040
17. Diehl G. E., Yue H. H., Hsieh K., Kuang A. A., Ho M., Morici L. A., Lenz L. L., Cado D., Riley L. W., Winoto A.: TRAIL-R as a negative regulator of innate immune cell responses. Immunity, 2004;21:877-889
18. Dimitriou I. D., Clemenza L., Scotter A. J., Chen G., Guerra F. M., Rottapel R.: Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins. Immunol. Rev., 2008;224:265-283
19. Divanovic S., Trompette A., Atabani S. F., Madan R., Golenbock D. T., Visintin A., Finberg R. W., Tarakhovsky A., Vogel S. N., Belkaid Y., Kurt-Jones E. A., Karp C. L.: Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat. Immunol., 2005;6:571-578
20. Divanovic S., Trompette A., Petiniot L. K., Allen J. L., Flick L. M., Belkaid Y., Madan R., Haky J. J., Karp C. L.: Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J. Leukoc. Biol., 2007;82:265-271
21. Dixit V. M., Green S., Sarma V., Holzman L. B., Wolf F. W., O'Rourke K., Ward P. A., Prochownik E. V., Marks R. M.: Tumor necrosis factor-α induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J. Biol. Chem., 1990;265:2973-2978
22. Dunne A., Ejdeback M., Ludidi P. L., O'Neill L. A., Gay N. J.: Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88. J. Biol. Chem., 2003;278:41443-41451
23. Fitzgerald K. A., Chen Z. J.: Sorting out Toll signals. Cell, 2006;125:834-836
24. Friedman C. S., O'Donnell M. A., Legarda-Addison D., Ng A., Cárdenas W. B., Yount J. S., Moran T. M., Basler C. F., Komuro A., Horvath C. M., Xavier R., Ting A. T.: The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep., 2008;9:930-936
25. Frobøse H., Rønn S. G., Heding P. E., Mendoza H., Cohen P., Mandrup-Poulsen T., Billestrup N.: Suppressor of cytokine Signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol. Endocrinol., 2006;20:1587-1596
26. Fukao T., Koyasu S.: PI3K and negative regulation of TLR signaling. Trends Immunol., 2003;24:358-363
27. Gainetdinov R. R., Premont R. T., Bohn L. M., Lefkowitz R. J., Caron M. G.: Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci., 2004;27:107-144
28. Hassan F., Islam S., Tumurkhuu G., Dagvadorj J., Naiki Y., Komatsu T., Koide N., Yoshida T., Yokochi T.: Involvement of interleukin-1 receptor-associated kinase (IRAK)-M in toll-like receptor (TLR) 7-mediated tolerance in RAW 264.7 macrophage-like cells. Cell. Immunol., 2009;256:99-103
29. Hayashi T., Gray C. S., Chan M., Tawatao R. I., Ronacher L., McGargill M. A., Datta S. K., Carson D. A., Corr M.: Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7. Proc. Natl. Acad. Sci. USA, 2009;106:2764-2769
30. Heyninck K., De Valck D., Vanden Berghe W., Van Criekinge W., Contreras R., Fiers W., Haegeman G., Beyaert R.: The zinc finger protein A20 inhibits TNF-induced NF-κB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-κB-inhibiting protein ABIN. J. Cell Biol., 1999;145:1471-1482
31. Hilton D. J.: Negative regulators of cytokine signal transduction. Cell. Mol. Life Sci., 1999;55:1568-1577
32. Hilton D. J., Richardson R. T., Alexander W. S., Viney E. M., Willson T. A., Sprigg N. S., Starr R., Nicholson S. E., Metcalf D., Nicola N. A.: Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. USA, 1998;95:114-119
33. Horng T., Barton G. M., Flavell R. A., Medzhitov R.: The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature, 2002;420:329-333
34. Hubbard L. L., Ballinger M. N., Thomas P. E., Wilke C. A., Standiford T. J., Kobayashi K. S., Flavell R. A., Moore B. B.: A role for IL-1 receptor-associated kinase-M in prostaglandin E2-induced immunosuppression post-bone marrow transplantation. J. Immunol., 2010;184:6299-6308
35. Ilangumaran S., Ramanathan S., Rottapel R.: Regulation of the immune system by SOCS family adaptor proteins. Semin. Immunol., 2004;16:351-365
36. Iwami K. I., Matsuguchi T., Masuda A., Kikuchi T., Musikacharoen T., Yoshikai Y.: Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J. Immunol., 2000;165:6682-6686
37. Janssens S., Beyaert R.: Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol. Cell, 2003;11:293-302
38. Janssens S., Burns K., Tschopp J., Beyaert R.: Regulation of interleukin-1- and lipopolysaccharide-induced NF-κB activation by alternative splicing of MyD88. Curr. Biol., 2002;12:467-471
39. Janssens S., Burns K., Vercammen E., Tschopp J., Beyaert R.: MyD88S, a splice variant of MyD88, differentially modulates NF-κB- and AP-1-dependent gene expression. FEBS Lett., 2003;548:103-107
40. Jeong E., Lee J. Y.: Intrinsic and extrinsic regulation of innate immune receptors. Yonsei Med. J., 2011;52:379-392
41. Jiang Z., Zamanian-Daryoush M., Nie H., Silva A. M., Williams B. R., Li X.: Poly (I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFκB and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J. Biol. Chem., 2003;278, 16713-16719
42. Kagan J. C., Medzhitov R.: Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell, 2006;125:943-955
43. Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K. J., Takeuchi O., Akira S.: IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol., 2005;6:981-988
44. Kile B. T., Schulman B. A., Alexander W. S., Nicola N. A., Martin H. M., Hilton D. J.: The SOCS box: a tale of destruction and degradation. Trends Biochem. Sci., 2002;27:235-241
45. Kinjyo I., Hanada T., Inagaki-Ohara K., Mori H., Aki D., Ohishi M., Yoshida H., Kubo M., Yoshimura A.: SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity, 2002;17:583-591
46. Kobayashi K., Hernandez L. D., Galán J. E., Janeway C. A. Jr., Medzhitov R., Flavell R. A.: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell, 2002;110:191-202
47. Kubo M., Hanada T., Yoshimura A.: Suppressors of cytokine signaling and immunity Nat. Immunol., 2003;4:1169-1176
48. Kulczycka L., Sysa-Jȩdrzejowska A., Robak E.: Udział receptorów Toll-like w patogenezie wybranych chorób skóry. Postȩpy Hig. Med. Dośw., 2010;64:364-371
49. Kumar H., Kawai T., Akira S.: Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun., 2009;388:621-625
50. Lagler H., Sharif O., Haslinger I., Matt U., Stich K., Furtner T., Doninger B., Schmid K., Gattringer R., de Vos A. F., Knapp S.: TREM-1 activation alters the dynamics of pulmonary IRAK-M expression in vivo and improves host defense during pneumococcal pneumonia. J. Immunol., 2009;183:2027-2036
51. Le Bouder E., Rey-Nores J. E., Rushmere N. K., Grigorov M., Lawn S. D., Affolter M., Griffin G. E., Ferrara P., Schiffrin E. J., Morgan B. P., Labéta M. O.: Soluble forms of Toll-like receptor (TLR) 2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J. Immunol., 2003;171:6680-6689
52. Lécart S., Lecointe N., Subramaniam A., Alkan S., Ni D., Chen R., Boulay V., Pène J., Kuroiwa K., Tominaga S., Yssel H.: Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur. J. Immunol., 2002;32:2979-2987
53. Lefkowitz R. J., Whalen E. J.: β-arrestins: traffic cops of cell signaling. Curr. Opin. Cell Biol., 2004;16:162-168
54. Li L., Soetandyo N., Wang Q., Ye Y.: The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochim. Biophys. Acta, 2009;1793:346-353
55. Li T., Hu J., Li L.: Characterization of Tollip protein upon lipopolysaccharide challenge. Mol. Immunol., 2004;41:85-92
56. Liew F. Y., Xu D., Brint E. K., O'Neill L. A.: Negative regulation of Toll-like receptor-mediated immune responses. Nat. Rev. Immunol., 2005;5:446-458
57. Lin S. C., Chung J. Y., Lamothe B., Rajashankar K., Lu M., Lo Y. C., Lam A. Y., Darnay B. G., Wu H.: Molecular basis for the unique deubiquitinating activity of the NF-κB inhibitor A20. J. Mol. Biol., 2008;376:526-540
58. Liu J., Buckley J. M., Redmond H. P., Wang J. H.: ST2 negatively regulates TLR2 signaling, but is not required for bacterial lipoprotein-induced tolerance. J. Immunol., 2010;184:5802-5808
59. Lo Y. L., Beckhouse A. G., Boulus S. L., Wells C. A.: Diversification of TOLLIP isoforms in mouse and man. Mamm. Genome, 2009;20:305-314
60. Luttrell L. M., Roudabush F. L., Choy E. W., Miller W. E., Field M. E., Pierce K. L., Lefkowitz R. J.: Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc. Natl. Acad. Sci. USA, 2001;98:2449-2454
61. Mabilleau G., Chappard D., Sabokbar A.: Role of the A20-TRAF6 axis in lipopolysaccharide-mediated osteoclastogenesis. J. Biol. Chem., 2011;286:3242-3249
62. Mansell A., Smith R., Doyle S. L., Gray P., Fenner J. E., Crack P. J., Nicholson S. E., Hilton D. J., O'Neill L. A., Hertzog P. J.: Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol., 2006;7:148-155
63. Martin T. F.: Phosphoinositide lipids as signaling molecules: common themes for signal transduction, cytoskeletal regulation, and membrane trafficking. Annu. Rev. Cell Dev. Biol., 1998;14:231-264
64. Martinon F., Pétrilli V., Mayor A., Tardivel A., Tschopp J.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature, 2006;440:237-241
65. McDonald P. H., Cote N. L., Lin F. T., Premont R. T., Pitcher J. A., Lefkowitz R. J.: Identification of NSF as a β-arrestin1-binding protein. Implications for β2-adrenergic receptor regulation. J. Biol. Chem., 1999;274:10677-10680
66. McGettrick, A. F., O'Neill L. A.: The expanding family of MyD88-like adaptors in Toll-like receptor signal transduction. Mol. Immunol., 2004;41:577-582
67. Medzhitov R.: Recognition of microorganisms and activation of the immune response. Nature, 2007;449:819-826
68. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J.: Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature, 2005;437:1167-1172
69. Meylan E., Tschopp J.: Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol. Cell, 2006;22:561-569
70. Meylan E., Tschopp J., Karin M.: Intracellular pattern recognition receptors in the host response. Nature, 2006;442:39-44
71. Mink M., Fogelgren B., Olszewski K., Maroy P., Csiszar K.: A novel human gene (SARM) at chromosome 17q11 encodes a protein with a SAM motif and structural similarity to Armadillo/β-catenin that is conserved in mouse, Drosophila, and Caenorhabditis elegans. Genomics, 2001;74:234-244
72. Miyake K., Yamashita Y., Ogata M., Sudo T., Kimoto M.: RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family. J. Immunol., 1995;154:3333-3340
73. Nagai Y., Kobayashi T., Motoi Y., Ishiguro K., Akashi S., Saitoh S., Kusumoto Y., Kaisho T., Akira S., Matsumoto M., Takatsu K., Miyake K.: The radioprotective 105/MD-1 complex links TLR2 and TLR4/MD-2 in antibody response to microbial membranes. J. Immunol., 2005;174:7043-7049
74. Nakagawa R., Naka T., Tsutsui H., Fujimoto M., Kimura A., Abe T., Seki E., Sato S., Takeuchi O., Takeda K., Akira S., Yamanishi K., Kawase I., Nakanishi K., Kishimoto T.: SOCS-1 participates in negative regulation of LPS responses. Immunity, 2002;17:677-687
75. Nallagatla S. R., Hwang J., Toroney R., Zheng X., Cameron C. E., Bevilacqua P. C.: 5'-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science, 2007;318:1455-1458
76. O'Neill L. A., Fitzgerald K. A., Bowie A. G.: The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol., 2003;24:286-290
77. Oguro A., Kubota H., Shimizu M., Ishiura S., Atomi Y.: Protective role of the ubiquitin binding protein Tollip against the toxicity of polyglutamine-expansion proteins. Neurosci. Lett., 2011;503:234-239
78. Opipari A. W. Jr., Boguski M. S., Dixit V. M.: The A20 cDNA induced by tumor necrosis factor α encodes a novel type of zinc finger protein. J. Biol. Chem., 1990;265:14705-14708
79. Park J. H., Kim Y. G., McDonald C., Kanneganti T. D., Hasegawa M., Body-Malapel M., Inohara N., Núñez G.: RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. J. Immunol., 2007;178:2380-2386
80. Pauleau A. L., Murray P. J.: Role of nod2 in the response of macrophages to toll-like receptor agonists. Mol. Cell. Biol., 2003;23:7531-7539
81. Peng J., Yuan Q., Lin B., Panneerselvam P., Wang X., Luan X. L., Lim S. K., Leung B. P., Ho B., Ding J. L.: SARM inhibits both TRIF- and MyD88-mediated AP-1 activation. Eur. J. Immunol., 2010;40:1738-1747
82. Perry S. J., Baillie G. S., Kohout T. A., McPhee I., Magiera M. M., Ang K. L., Miller W. E., McLean A. J., Conti M., Houslay M. D., Lefkowitz R. J.: Targeting of cyclic AMP degradation to β2-adrenergic receptors by β-arrestins. Science, 2002;298:834-836
83. Pitti R. M., Marsters S. A., Ruppert S., Donahue C. J., Moore A., Ashkenazi A.: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 1996;271:12687-12690
84. Qin J., Qian Y., Yao J., Grace C., Li X.: SIGIRR inhibits interleukin-1 receptor- and Toll-like receptor 4-mediated signaling through different mechanisms. J. Biol. Chem., 2005;280:25233-25241
85. Rothenfusser S., Goutagny N., Di Perna G., Gong M., Monks B. G., Schoenemeyer A., Yamamoto M., Akira S., Fitzgerald K. A.: The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J. Immunol., 2005;175:5260-5268
86. Ryo A., Suizu F., Yoshida Y., Perrem K., Liou Y. C., Wulf G., Rottapel R., Yamaoka S., Lu K. P.: Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell, 2003;12:1413-1426
87. Sasaki A., Yasukawa H., Shouda T., Kitamura T., Dikic I., Yoshimura A.: CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J. Biol. Chem., 2000;275:29338-29347
88. Sato S., Sugiyama M., Yamamoto M., Watanabe Y., Kawai T., Takeda K., Akira S.: Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-κB and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol., 2003;171, 4304-4310
89. Schaefer U., Voloshanenko O., Willen D., Walczak H.: TRAIL: a multifunctional cytokine. Front. Biosci., 2007;12:3813-3824
90. Seki M., Kohno S., Newstead M. W., Zeng X., Bhan U., Lukacs N. W., Kunkel S. L., Standiford T. J.: Critical role of IL-1 receptor-associated kinase-M in regulating chemokine-dependent deleterious inflammation in murine influenza pneumonia. J. Immunol., 2010;184:1410-1418
91. Seth R. B., Sun L., Chen Z. J.: Antiviral innate immunity pathways. Cell Res., 2006;16:141-147
92. Seth R. B., Sun L., Ea C. K., Chen Z. J.: Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell, 2005;122:669-682
93. Sims J. E., Smith D. E.: The IL-1 family: regulators of immunity. Nat. Rev. Immunol., 2010;10:89-102
94. So E. Y., Ouchi T.: The application of Toll like receptors for cancer therapy. Int. J. Biol. Sci., 2010;6:675-681
95. Sweet M. J., Leung B. P., Kang D., Sogaard M., Schulz K., Trajkovic V., Campbell C. C., Xu D., Liew F. Y.: A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J. Immunol., 2001;166:6633-6639
96. Takahasi K., Yoneyama M., Nishihori T., Hirai R., Kumeta H., Narita R., Gale M. Jr., Inagaki F., Fujita T.: Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol. Cell, 2008;29:428-440
97. Takeuchi O., Akira S.: MDA5/RIG-1 and virus recognition. Curr. Opin. Immunol., 2008;20:17-22
98. Takezako N., Hayakawa M., Hayakawa H., Aoki S., Yanagisawa K., Endo H., Tominaga S.: ST2 suppresses IL-6 production via the inhibition of IκB degradation induced by the LPS signal in THP-1 cells. Biochem. Biophys. Res. Commun., 2006;341:425-432
99. Turer E. E., Tavares R. M., Mortier E., Hitotsumatsu O., Advincula R., Lee B., Shifrin N., Malynn B. A., Ma A.: Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J. Exp. Med., 2008;205:451-464
100. Vereecke L., Sze M., Mc Guire C., Rogiers B., Chu Y., Schmidt-Supprian M., Pasparakis M., Beyaert R., van Loo G.: Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp. Med., 2010;207:1513-1523
101. Verstrepen L., Verhelst K., van Loo G., Carpentier I., Ley S. C., Beyaert R.: Expression, biological activities and mechanisms of action of A20 (TNFAIP3). Biochem. Pharmacol., 2010;80:2009-2020
102. Walczak H., Miller R. E., Ariail K., Gliniak B., Griffith T. S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R. G., Rauch C. T., Schuh J. C., Lynch D. H.: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med., 1999;5:157-163
103. Wang J., Hu Y., Deng W. W., Sun B.: Negative regulation of Toll-like receptor signaling pathway. Microbes. Infect., 2009;11:321-327
104. Wang Y., Tang Y., Teng L., Wu Y., Zhao X., Pei G.: Association of β-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat. Immunol., 2006;7:139-147
105. Watanabe T., Kitani A., Murray P. J., Strober W.: NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol., 2004;5:800-808
106. Weber F., Wagner V., Rasmussen S. B., Hartmann R., Paludan S. R.: Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol., 2006;80:5059-5064
107. Wertz I. E., O'Rourke K. M., Zhou H., Eby M., Aravind L., Seshagiri S., Wu P., Wiesmann C., Baker R., Boone D. L., Ma A., Koonin E. V., Dixit V. M.: De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature, 2004;430:694-699
108. Wiley S. R., Schooley K., Smolak P. J., Din W. S., Huang C. P., Nicholl J. K., Sutherland G. R., Smith T. D., Rauch C., Smith C. A., Rauch Ch., Smith C. A., Goodwin R. G.: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995;3:673-682
109. Windheim M., Lang C., Peggie M., Plater L. A., Cohen P.: Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem. J., 2007;404:179-190
110. Witherow D. S., Garrison T. R., Miller W. E., Lefkowitz R. J.: β-arrestin inhibits NF-κB activity by means of its interaction with the NF-κB inhibitor IκBα. Proc. Natl. Acad. Sci. USA, 2004;101:8603-8607
111. Xiao H., Gulen M. F., Qin J., Yao J., Bulek K., Kish D., Altuntas C. Z., Wald D., Ma C., Zhou H., Tuohy V. K., Fairchild R. L., de la Motte C., Cua D., Vallance B. A., Li X.: The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity, 2007;26:461-475
112. Xu L. G., Wang Y. Y., Han K. J., Li L. Y., Zhai Z., Shu H. B.: VISA is an adapter protein required for virus-triggered IFN-β signaling. Mol. Cell, 2005;19:727-740
113. Yamakami M., Yoshimori T., Yokosawa H.: Tom1, a VHS domain-containing protein, interacts with tollip, ubiquitin, and clathrin. J. Biol. Chem., 2003;278:52865-52872
114. Yamamoto M., Sato S., Hemmi H., Sanjo H., Uematsu S., Kaisho T., Hoshino K., Takeuchi O., Kobayashi M., Fujita T., Takeda K., Akira S.: Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature, 2002;420:324-329
115. Yasukawa H., Misawa H., Sakamoto H., Masuhara M., Sasaki A., Wakioka T., Ohtsuka S., Imaizumi T., Matsuda T., Ihle J. N., Yoshimura A.: The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J., 1999;18:1309-1320
116. Yin H., Huang B. J., Yang H., Huang Y. F., Xiong P., Zheng F., Chen X. P., Chen Y. F., Gong F. L.: Pretreatment with soluble ST2 reduces warm hepatic ischemia/reperfusion injury. Biochem. Biophys. Res. Commun., 2006;351:940-946
117. Yoneyama M., Fujita T.: Function of RIG-I-like receptors in antiviral innate immunity. J. Biol. Chem., 2007;282:15315-15318
118. Yoneyama M., Kikuchi M., Matsumoto K., Imaizumi T., Miyagishi M., Taira K., Foy E., Loo Y. M., Gale M. Jr., Akira S., Yonehara S., Kato A., Fujita T.: Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J. Immunol., 2005;175:2851-2858
119. Yoshida H., Jono H., Kai H., Li J. D.: The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for Toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7 J. Biol. Chem., 2005;280, 41111-41121
120. Yoshimura A., Naka T., Kubo M.: SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol., 2007;7:454-465
121. Yuk J. M., Jo E. K.: Toll-like receptors and innate immunity. J. Bacteriol. Virol., 2011;41:225-235
122. Yuk J. M., Shin D. M., Lee H. M., Kim J. J., Kim S. W., Jin H. S., Yang C. S., Park K. A., Chanda D., Kim D. K., Huang S. M., Lee S. K., Lee C. H., Kim J. M., Song C. H., Lee S. Y., Hur G. M., Moore D. D., Choi H. S., Jo. EK.: The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat. Immunol., 2011;12:742-751
123. Zacharioudaki V., Androulidaki A., Arranz A., Vrentzos G., Margioris A. N., Tsatsanis C.: Adiponectin promotes endotoxin tolerance in macrophages by inducing IRAK-M expression. J. Immunol., 2009;182:6444-6451
124. Zhang G., Ghosh S.: Negative regulation of toll-like receptor-mediated signaling by Tollip. J. Biol. Chem., 2002;277:7059-7065
125. Zhang S., Guo D., Jiang L., Zhang Q., Qiu X., Wang E.: SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro. BMC Cancer, 2008;8:150